NEW YORK (Reuters Health)—Antibodies to infliximab in patients with inflammatory bowel disease (IBD) treated with Janssen’s Remicade cross-react with the biosimilar Remsima from Celltrion (distributed as Inflectra by Hospira in the U.S.), researchers from Israel report. “The cross-reactivity of anti-Remicade antibodies with Remsima attests to shared immune triggering points (epitopes) on these two agents, and…
Biosimilar for Infliximab Launched in Europe
Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information
The ACR Recommends Cautious Approach as Biosimilars Enter U.S. Market
With the U.S. FDA’s first approval of a biosimilar drug earlier this month, rheumatologists stress the need to ensure safety, efficacy of such drugs in treating rheumatic diseases
Update on Legislation, Advocacy Efforts to Advance Rheumatology
Status of progess to fix sustainable growth rate physician formula, other rheumatology-related issues facing Congress
EULAR 2014: Biosimilar Drug Production Raises Concerns
Rheumatology experts question biosimilars’ safety, efficacy given their complex production process
Rheumatology Advocacy Starts at Home
The ACR expands advocacy efforts to impact state legislatures, local organizations
Rheumatology Drug Updates, Trials, Safety Data
Legislative news on biosimilars, safety warning on epidural corticosteroid injections, and other drug updates rheumatologists need to know
What’s New in Inflammatory Arthritis?
Rheumatology experts at the ACR’s State-of-the-Art Clinical Symposium in Chicago discuss latest drug therapies, insights into axial spondyloarthritis and bone erosion, repair
Why Tweaking Molecular Structures Can Be Hazardous to Our Health
The rise and fall of rofecoxib and valdecoxib demonstrate the need for caution in new drug development
Update on Healthcare Reform in 2014 under the Affordable Care Act
The American College of Rheumatology continues to monitor healthcare system changes under the ACA; educate rheumatologists, rheumatology health professionals